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From the Editors . . .
At The George Washington University School of Medicine and Health Sciences, we are
fortunate to have exceptional research opportunities available to us in diverse and exciting
fields.  Some of the projects medical students have undertaken involve basic science re-
search, others involve clinical research and health policy, and several include international
medical experiences.  In recent years, the development of Track Programs and the number
of fellowships offered by the Office of Student Opportunities have dramatically increased
these worthwhile opportunities.
By establishing a scientific medical student journal named Fusion, which we hope will
be published annually, we aim to capture the excitement of the many research-related
endeavors of our peers and give members of the broader scientific and medical community
an opportunity to learn about the comprehensive and multi-layered experiences of GW
medical students.  We are hopeful that Fusion will entice current and future students to
engage in the many research opportunities available and share their experiences.
Responses to our call for submissions to Fusion exceeded our expectations. We received
22 submissions, demonstrating the pressing need and desire of our peers for an opportu-
nity to write about and share their work.  Our decision to solicit submissions from mem-
bers of both the Classes of 2009 and 2010 acknowledges our understanding that the
number of GW students who enter with previous research experience is rapidly increasing
and that the work they have undertaken is valuable to us.  Members of the Student Edito-
rial Board, consisting of elected officers of the William Beaumont Research Honor Society,
reviewed each submission selected for publication. Responsibility for the content of each
article, however, remains with its author.
We thank W. Scott Schroth, MD, MPH, and James Scott, MD, FACEP, in the Office
of the Deans; Anne Hirshfield, PhD, in the Office of Research; Linda Dent, Thom
Kohout, Debbie Goldstein and Abby Vogel in the Office of Marketing and Communica-
tions; and Rachel Mazzotta and Chistopher D’Avella in the Office of Student Opportuni-







Many would say that the opportunity to practice medi-
cine is, by itself, a sufficiently noble and rewarding career.
However, the real beauty of the field is that it offers one so
many possible avenues to contribute to the health of indi-
viduals and society.  Not only are
there a multitude of different
clinical specialties, but also, one
may contribute through research,
education, administration and
community service.  Most impor-
tantly, all of these contributions
can be carried forward as scholarly
disciplines, adding not only to the
health of people, but also to the
advancement of medicine as a
field.
This new journal, conceived
and carried forward by students
dedicated to scholarly investiga-
tion, is a testament to the array of
talents and interests among our
diverse and accomplished student body.  I commend both
the students who have organized this journal and all of
those who have contributed their work to its pages.
When Dean James Scott was appointed several years
ago, he articulated an important vision for the education
of our medical students.  Building on a solid foundation
of medical education in basic and clinical sciences, he
wanted to enable students to pursue their unique interests
by taking advantage of the many opportunities afforded by
the School of Medicine and Health Sciences and through
our close relationships with the School of Public Health
and Health Services, other schools in
the University and organizations
throughout the District of Columbia.
Indeed, GW exists in a landscape that
is unique and rich with opportunity.
Over the past several years, the work
of many has supported this vision.
The Beaumont Research Society, the
Office of Student Opportunities, the
Office of International Medical Pro-
grams and the Program in Medical
Humanities now form a unique infra-
structure to support the scholarly
interests of medical students
throughout their four years at GW.
The contributions to Fusion are testa-
ment to the success of this effort, and
to the curiosity and hard work of our students.
W. Scott Schroth, MD, MPH
Senior Associate Dean for Academic Affairs
from the dean’s office. . .
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It is with great pleasure that I in-
troduce to you the inaugural issue
of Fusion, a compilation of articles
submitted by some of GW’s most
promising medical students.
These students are members of
GW’s William Beaumont Medical
Research Honor Society.  The Beau-
mont Society was established at
the GW School of Medicine in
1935 to promote student research
and there are many accomplished
scientists throughout the country
who list membership in the society
amongst their honors.
The articles in this book de-
scribe various short term research
projects performed by Beaumont
students during the summer of 2006.  Most of these stu-
dents were supported by stipends from the WT Gill En-
dowment which has provided our medical students with
the resources to experience what biomedical research en-
tails.  In 2006, we were fortunate to be able to provide
more opportunities to students due to the additional sti-
pends made available through generous gifts from an
anonymous donor, as well as from Dr. Jane Klein and Dr.
Robert D. Rosenberg (Medicine ’61), a graduate of our
Medical School who has had a distinguished career in bio-
medical research. We are grateful for these generous dona-
tions that enable us to provide intensive short-term re-
search experiences for our students.  The opportunity to
experience research first-hand is invaluable at this stage in
these students’ education as they decide whether a career
as a clinician/researcher is the right path for them. In
2006, we were fortunate to be able to provide more op-
portunities to students due to the additional stipends
made available through generous gifts from an anonymous
donor, Drs. Gerald (Medicine ’63) and Audrey Lazarus;
Christopher Barley, MD ’93; Keshav Narain, MD ’92;
from the research office. . .
Charles Walkoff, MD ’59; Robert
Rosenberg, MD ’61; and Jane Klein.
Fusion is a testament, not only to
the creativity and accomplishments of
our medical students, but also to the
creativity and commitment of the stu-
dent leaders of the Beaumont Society.
I want to especially recognize Andrew
Lerner, President of the Beaumont So-
ciety, and Rahul Araya, the Society’s
Research Journal Chair.  These stu-
dents conceived of the idea to produce
this issue and worked tirelessly to make
it happen. Remarkably, they managed
to find time for this extracurricular
activity while managing the demands
of the second-year curriculum.  Recog-
nition also goes to the GW staff mem-
bers who contributed to this effort, especially Linda Dent,
Medical Center Communications Director, who gave gener-
ously of her time and valuable guidance, and Abby Vogel,
who worked with the students with the editing and lay-
out, along with Debbie Goldstein and Thomas Kohout,
all from the Communications and Marketing Office.
Thanks also to Sarah Hassaine, Health Research Information
Support Specialist, for her editing and suggestions.
As you flip through the proceeding pages and see first-
hand the varied interests of GW’s students, we hope that
you will appreciate all the hard work that our students
have put forward.  I’m sure their mentors would agree that
these students have given back more than they received;
having them in our labs and clinics greatly enriches our




Smoke-Free Children’s National Medical Center Campus
Rahul Arya, MSII,
Community Health Track
Advisor: Dana Best, MD, MPH
Children’s National Medical Center
Washington, DC
cember 31, 1993.5 Ninety-
six percent of hospitals met
this JCAHO tobacco control
standard.5
A number of hospitals
throughout the country have
taken this smoke-free stan-
dard further and made their
entire campuses smoke free,
meaning that no smoking is
allowed in campus buildings
or on the surrounding
grounds and ramps.
The major factor behind
going smoke free was recog-
nition of the fact that
healthcare facilities must
promote smoking cessation
and serve as role models.
The smoking policy at the
Mayo Medical Center in
Minnesota recognizes its
obligation to its patients and
the public to strongly assert
the risks of tobacco use by
establishing a smoke-free
campus.6 The University of
Michigan Health System
implemented a campus-wide
smoke-free policy in Febru-
ary 1999 to “help people
take control of their health”
and “to create healthy com-
munities.”7  Advocates of
campus-wide smoking bans
argue that providing a place
to smoke does not support a
healthcare institution’s goal
and mission to provide a
healthier environment for
patients, visitors and em-
ployees.7
At Children’s National
Medical Center (CNMC) in
Washington, DC, the official
smoking policy prohibits
smoking on hospital pre-
mises, including all buildings
and parking areas. The des-
ignated smoking area is a
booth located outside the
Emergency Room entrance.
However, there are no clear
guidelines on tobacco use on
other parts of the campus,
nearby grounds, ramps and
adjacent sidewalks. As a
result, people frequently
smoke in CNMC’s
entranceways and on the





if implemented at CNMC,
would provide a healthier
environment for patients,
employees and visitors, and
would further the hospital’s
mission statement. It could
also promote smoking cessa-






and toxic. What do these
substances have in common?












beyond smokers to non-
smokers involuntarily ex-
posed to secondhand smoke
(SHS).1 In the U.S., SHS has
been linked to at least
53,000 non-smoker deaths
each year,2,3 including 3,400
deaths from lung cancer,
43,000 from cardiac-related
illnesses and 430 from Sud-
den Infant Death Syndrome
(SIDS).4
 These statistics make it
imperative that hospitals be
smoke free. In 1991, The
Joint Commission on Ac-
creditation of Health Orga-
nizations (JCAHO) an-
nounced a tobacco control
standard for accredited
American hospitals that
mandated that hospital build-
ings be smoke free by De-
health policy issues. . .
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Emergency Departments
(EDs) are in a state of crisis
as they struggle to manage a
surging demand with insuffi-
cient resources. Emergency
room visits have risen an
average of 3.7 percent over
the last five years,1 making
EDs the primary source of
healthcare for many Ameri-
cans.2
Consequently, EDs have
become crowded and unable
to readily care for such a
large patient population. It is
therefore necessary to find a
way to moderate demand
and improve the quality of
patient healthcare.3
One method hospitals
currently use to relieve
crowding and limit patient
outflow is through ambu-
lance diversion. In the event
that an ED feels it cannot
safely accept additional pa-
tients, it can request that
Speeding for a Solution:
Ambulance Diversion and the ED Crowding Crisis
Rachel Kastl-Casey, MSII,
Health Policy Track
Advisors: Bruce Siegel, MD, MPH, and
Marcia Wilson, MBA, PhD (candidate)
Department of Health Policy,
The George Washington University
Medical Center
Washington, DC
ambulances be diverted to an
alternate hospital.
Although ambulance di-
version was initially intended
to be a temporary solution,
it has become an increas-
ingly routine response to the
escalating ED crowding cri-
sis. However, widespread
use of this measure has had
unintended consequences
that compound, rather than
relieve, the problem of
crowding. The increased
practice of diverting ambu-
lances to less crowded hospi-
tals has led to increased pa-
tient transport time, in-
creased paramedic turn-
around time and decreased
ambulance availability.4 Ef-
forts are now being made to
reduce diversion as a re-
sponse to ED overcrowding.
Establishing policy and
regulations for managing
diversion has proven to be a
significant challenge. With-
out sufficient federal atten-
tion on the issue, responsi-
bility has fallen to states and
local communities. In an
investigation of major initia-
tives, three states and three
local communities stood out
in their efforts to manage
ambulance diversion. Al-
though they differed in man-
agement style, each sought to
find some standardized fash-
ion to manage and decrease
diversion.
Massachusetts, New York
and Arizona produced writ-
ten guidelines to direct hos-
ployees and send a strong
message to the community
about the harmful effects of
smoking. To further this
message, research is cur-
rently underway at CNMC
to assess employee, patient
and visitor attitudes toward
making the entire campus
smoke free. The results of
the study will be used to
develop a proposal to intro-
duce a campus-wide smok-
ing ban at CNMC.
CNMC is currently
ranked ninth among all pedi-
atric hospitals nationwide by
US News and World Report.8
It is high time that a nation-
ally recognized healthcare
institution with a mission “to
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Impact of Medicare Part D on Prescription Drug
Coverage for Patients with Chronic Conditions
Shakti Nayar, MSII, Health Policy Track
Advisor: Janice Blanchard, MD
Emergency Department,
The George Washington University
Medical Center
Washington, DC
President Bush enacted the
Medicare Prescription Drug,
Improvement, and Modern-
ization Act of 2003 in De-
cember 2003. At its core
was Medicare Part D, a vol-
untary benefit intended to
decrease prescription drug
costs for Medicare enrollees.
Starting in 2004, Medi-
care enrollees could purchase
Medicare drug discount
cards to buy prescriptions at
a discount. This program
ended on January 1, 2006,
when the full Medicare Part
D drug benefit began for
those who enrolled by No-
vember 15, 2005.
Rather than having one
uniform plan for all Medi-
care Part D enrollees, there
were a number of plans pro-
vided by various private
companies that differed in
types of cost sharing and
drug formularies. Medicare
beneficiaries had to deter-
mine which of the many
plans was best for them and
enroll in Part D indepen-
dently.1 Some enrollees were
previously enrolled in drug
plans that provided more
cost savings than the Part D
plans to which they
switched.2,3 Determining
whether to enroll in Part D
and choosing a specific plan




department is a critical ac-
cess site, it was a useful loca-
tion to study prescription
drug coverage as part of
care. Study participants were
recruited from patients pre-
senting to The George Wash-
pitals regarding how to
implement a diversion re-
duction plan. Massachusetts
mandated several detailed
plans and procedures for
hospitals to follow, while
New York and Arizona cre-
ated guidelines that gave
hospitals the autonomy to
develop their own specific
protocols. Massachusetts
provided the most direction
and subsequently displayed









San Diego and Sacramento
produced detailed protocols
that focused on hospital op-
erational improvements to
reduce crowding and hence
decrease the need for diver-
sion, while Syracuse put
minimal restrictions on hos-
pitals, allowing them to de-
velop their own strategies.
These community col-
laborations showed signifi-
cantly greater reduction in
diversion hours than those
reported in statewide initia-
tives. With smaller areas and
fewer stakeholders (e.g.,
hospitals), communities were




Ambulance diversion is a
flawed solution to ED
crowding that requires ur-
gent attention on a national
level. Without a national
standard in place, some
states and communities have
worked to create their own
protocols, resulting in im-
provements as well as incon-
sistencies throughout the
country. The time has come
for federal guidance in creat-
ing a unified, proven stan-
dard for states and local
communities to use. The
federal government must
take responsibility for this
problem by developing na-
tional evidence-based diver-
sion reduction policies and
protocols. Implementing
proven solutions through a
national effort will help states
and communities achieve
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greater than $14,000 used
private insurance or self-paid
for prescriptions.
Analysis of OOP costs
showed that respondents not
enrolled in Part D were
more likely to have increased
OOP costs of more than $50
per month post-implementa-
tion (Figure 2). Respondents
using Medicaid for prescrip-
tions pre-Part D were dually
eligible Medicaid-Medicare
enrollees and were least
likely to have high OOP
costs. Post-implemen-
tation, the percentage
of Part D respondents
spending more than
$50 per month was
less than for the other
insurance categories,
but higher than for
Medicaid pre-Part D.
Medicare beneficia-
ries not using Part D
post-implementation
were asked why they
didn’t enroll and the
most common re-
sponse was “never
heard of it” (66 per-
cent).
In order to better
determine the impli-
cations of Part D, a
Figure 2. Respondents not enrolled in Part D were more likely to have OOP costs of more than
$50 per month. Respondents using Medicaid for prescriptions pre-Part D were dually eligible
Medicaid-Medicare enrollees and were least likely to have high OOP costs. Post-implementation,
the percentage of Part D respondents spending more than $50 per month was less than for





of their primary com-






a primary survey with
basic demographic
questions and ques-
tions to evaluate barri-
ers to care, including
access to prescription
medications. Univariate
analysis was used to assess
the relationship between the
outcomes of interest and
main demographic variables.
A total of 862 surveys
were collected between
March 1, 2004 and August
1, 2006, and a pilot cross-
sectional analysis of the
Medicare subpopulation was
performed. There were 152
Medicare respondents pre-
implementation of Part D
and 38 respondents post-
implementation. Methods of
payment for prescriptions




type to income, respondents




Part D more than any other
type of payment (Figure 1).
After implementation, the
majority of respondents in
the same income bracket
reported using Medicare
Part D to obtain prescription
medications than other pay-
ment method. The majority
of respondents with a salary
Figure 1. Respondents with lower
incomes were more likely to use
Medicare drug discount cards pre-
implementation and Medicare Part D
post-implementation. Respondents
with higher incomes were more likely
to use private insurance or self-pay
pre-implementation. The percentage
of respondents that used private
insurance increased to 50 percent
post-implementation.
2. Kaiser Family Foundation.
Seniors’ Early Experiences
with Their New Medicare
Drug Plans.  www.kff.org.
3. Mallya G, Bazemore A,
Phillips R, Green L, Klein L,
Dodoo M. Out-of-pocket
prescription costs a continuing
burden under Medicare Part
D.  www.graham-center.org.
4. Henley E. Medicare prescrip-
tion drug bill: Resources to
inform and equip your pa-
tients. Journal of Family Prac-
tice. January 2006;55(1):41-
44.
larger sample is needed.
However, preliminary results
of the cross-sectional analysis
indicate that Medicare re-
cipients may not fully under-
stand the benefit of Part D,
despite government efforts to
increase enrollment.
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Improving Medical School Curricula:
Examining Basic Science Lectures and Assessments
Marc Lener, MSII, Medical Education Track
Advisors: James Brawer, PhD, and
Yvonne Steinert, PhD
McGill University Centre for Medical
Education
Montreal, Quebec, Canada
I entered medical school
interested in pursuing a ca-
reer in both medicine and
medical education. As a par-
ticipant in the Medical Edu-
cation Track, I have been
able to pursue this profes-
sional goal.
This past summer, I
crossed the border into Ca-
nadian territory and had the
opportunity to work on two
separate projects focused on
two major areas of basic
science medical curriculum:
basic science lectures and
the quality of basic science
assessments. This article
provides a brief history of
medical school curriculum
and a synopsis of the two
projects on which I worked
at McGill University in
Montreal, Quebec, Canada.
Since the publication of
the Flexner Report in 1910,1
medical schools in the
United States and Canada
have divided their curricula
into separate biomedical
science and clinical educa-
tions. The basic science cur-
riculum is didactic—requir-
ing students to sit through
lectures organized by course
directors and deans and then
later assessed by in-house
examinations to hold stu-
dents accountable for the
information presented to
them. These two processes
govern how medical educa-
tors organize their curricula
and dictate how students
learn and prepare to succeed
in medical school courses.
Throughout the last century,
the traditional views of
medical curricula have been
challenged.




learning curriculum that has
evolved and been adopted by
many American and Cana-
dian medical schools. It was
met with relatively insignifi-
cant success; medical schools
are now attempting to imple-
ment an organ-system ap-
proach to their basic science
curricula. This approach to
learning medicine investi-
gates each organ system by
integrating normal structure
and function with pathologi-
cal processes and pharmaco-
logical intervention. Lastly,
lectures have become less
didactic and more student
centered, and examinations
emphasize clinical applica-
tion and analysis. Unfortu-
nately, this reform has been
slow moving and narrow
reaching.
At McGill University, my
























on Medical Education to
reduce lecturing hours. The
value of lecture has been a
controversial topic in higher
education and has been
negatively reviewed by the
popular press and various
educational journals. How-
ever, never before have re-
search studies asked medical
students their opinions about
the value of lecture and the
role that it plays in learning
medicine. Through question-
naires, medical students
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were asked their opinions
about basic science lectures.
Responses were catego-
rized into themes and rated
based on frequency. Of 150
students in the class, 50
completed questionnaires
were submitted. Students’
views on lecture were gener-
ally positive, and the follow-
ing themes were uncovered.
Lectures:
• Provided focus or empha-
sis on the material
• Provided an overview or
“big picture” of course
• Explained or resolved
difficulties in the notes or
other readings
• Reinforced learning by
hearing and seeing the
information
• Provided depth, insights
and examples not in read-
ings
• Allowed for a time-effi-
cient way to learn
• Provided exposure to and
interaction with experts
or role models
• Encouraged structure and
discipline
• Soothed anxiety about the
material.
Limited to one medical
school and only one-third of
one class of students, the
results of this preliminary
study showed that students
value lecture in ways that
cannot be substituted by any
other teaching methodology.
However, if the lecture is
valuable, one might wonder
how other teaching method-
ologies can complement the
value that is inherent to the
lecture. A research paper on
this topic is in preparation.
My second project fo-
cused on the quality of medi-
cal school examinations.
While this project was not
part of my original summer
project goals, my curiosity
and passion for methodolo-
gies in medical testing prod-
ded me to initiate several
discussions with Centre di-
















field of medical test develop-
ment and became inspired to
present my findings to the
faculty of The George Wash-
ington University School of
Medicine and Health Sci-
ences (SMHS). Among the
group of test experts, I was
able to communicate with
Susan Case, PhD, and
David Swanson, PhD, psy-
chometricians and inventors




Board of Medical Examiners
1-3). They provided impor-
tant focus points and wis-
dom from their experiences
working with medical school
faculty on test development.
The following is an abstract
from my analysis:2
Medical school faculty in
U.S. medical schools design
in-house assessments that
often consist of 50 or more
multiple-choice questions
(MCQs). The quality of
medical school MCQs is
undoubtedly dependent on
the level of questions that are
asked. However, a common
problem with writing in-
house examinations is that

















play a critical role in learn-
ing.4 Medical school MCQs
must go beyond knowledge
and offer a greater propor-
tion of higher-level questions
that emphasize application of
knowledge, analysis, integra-
tion and synthesis. The
USMLE Step examinations
are well constructed and
reviewed such that they offer
a variety of question types
and test a wide range of cog-
nitive skills.3 Thus, medical
faculty must learn from the
USMLE and construct ex-
aminations that allow stu-
dents to learn at a higher
taxonomic level. Further-
more, if low-quality exami-
nations are administered to
students, then students will
be less prepared to perform
well on other assessments of
higher-order thinking, like
the USMLE.
Jozefowicz et al’s paper
includes an excerpt from the
2002 report on in-house
medical school examina-
tions.5 Within their discus-
sion, the authors state, “Fac-
ulty responsible for writing
examinations should be
trained; writing good exami-
nation questions is a skill
that can be learned…a com-
mittee should review, cri-
tique and approve the con-
tent and format of the final
draft of the examination.”5
I hope to share what I
have learned from the wealth
of existing medical education
research with the medical
faculty and deans at the GW
SMHS to help implement
changes to basic science
assessments.
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in ways that can-
not be substituted
by any other teach-
ing methodology.
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Equivalency of Cancer Detection in Analog
Mammography versus Digitized Analog Mammography
Vivek Patil, MSII, Research Track
Advisor: Rachel F. Brem, MD
Department of Radiology,
The George Washington University
Medical Center
Washington, DC
over film, this study was
both necessary and timely.
One benefit of digitized
mammography is that image
settings, such as contrast and
zoom, can be adjusted.
Other advantages include the
ability to store and transmit
images in an electronic for-
mat. This prevents losing
films and facilitates consulta-
tion with other radiologists
who may be off site.
In this study conducted at
The George Washington
University Medical Center,
the equivalency of analog
mammography and digitized
analog mammography was
assessed with respect to can-
cer detection rates. If both
viewing conditions, analog
and digitized analog, de-









the traditional x-ray and film
variety used for decades, is
the gold standard for breast
cancer screening. However,
sensitivity for breast cancer
detection is only 85 percent,
and therefore, 15 percent of
screened cancers are over-
looked.1
Despite the imper-




rate of breast cancer.2
Yearly mammograms
after age 50 are im-
portant because prog-
nosis is best when the
cancer is detected
early.
The goal of this
study was to establish
equivalency between tradi-
tional screen-film mammog-
raphy and digitized analog
mammography. A digitized
analog mammogram is a
traditional screen-film mam-
mogram that has been digi-
tized for evaluation on a
softcopy workstation, or
computer with a high-resolu-
tion monitor specifically
designed for radiology appli-
cations.
Since there are advantages
to using the digital medium
would be able to experience
the benefits of digital images
without spending the large
sums of money required for
conversion to full-field digital
mammography. Full-field
digital mammography allows
images to be captured di-
rectly on the computer with-
out the intermediate film
step required for digitized
analog mammography.
Approval from the Institu-
tional Review Board was
obtained in March 2006 for
this study involving 200 pa-
tients. Informed consent was
waived because this study
was retrospective and only
used medical records.
Mammograms were ob-
tained from the Breast Care
Center at The George Wash-
ington University Hospital in
Washington, DC. Cases
clinical practice. . .
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for years to come. In addi-
tion, valuable experience was
gained planning and con-
ducting this research, which
led to a strong interest in a
career in Radiology—a field
that utilizes modern technol-
ogy and clinical knowledge.
REFERENCES:
1. Rosenberg E, Hunt W,
Williamson M, et al. Effects of
age, breast density, ethnicity,
and estrogen replacement
therapy on screening mammo-
graphic sensitivity and cancer
stage at diagnosis: review of
183,134 screening
mammograms in Albuquerque,
New Mexico. Radiology. 1998;
209:511-518.
2. Lewin J, D’orsi C, Hendrick
R. Digital Mammography.
Radiologic Clinics of North
America. 2004;42(5):871-884.
Benefit of Intra-Articular Corticosteroid Injection
Under Fluoroscopic Guidance for Subtalar Arthritis in
Juvenile Idiopathic Arthritis
Sandy Cho, MSI, Research Track
Advisor: Anne Marie Cahill, MD














50,000 children in the U.S.
Symptoms can be acute,
lasting for weeks to months,
or they can be chronic, last-
ing for months to years.
were digitized with
TotalLook (Icad, Inc.,




with two high-resolution 21-
inch grayscale monitors.
Films were digitized and
a multi-reader multi-case
receiver operating character-
istic (ROC) study was con-
ducted to assess equivalency
of analog and digitized ana-
log mammograms for cancer
detection. Each radiologist
reader was required to read
the same 200 cases on tradi-
tional film and softcopy
workstation. Each radiologist
chose the lighting conditions
and a magnifying glass was
provided. All identifiable
patient information was hid-
den except for age. In order
to prevent radiologists from
remembering specific
mammograms, a minimum
of four weeks elapsed be-
tween the two reading condi-
tions and the sequence in
which the cases were pre-
sented was randomized. Five
readers and 200 cases were
used to obtain sufficient
statistical power.
To determine whether a
radiologist detected a cancer
correctly, the Breast Imaging
Reporting and Data System
(BIRADS) developed by the
American College of Radiol-
ogy was used. The BIRADS
score and location were col-
lected for each case.
BIRADS scores range from
one (negative finding) to five
(highly suggestive of malig-
nancy). True positives were






were included in the study.
Only malignant lesions that
were ductal carcinoma in
situ (DCIS) or invasive car-
cinoma one centimeter or
less were used in the study.
These small cancer sizes
were used because equiva-
lency between the two read-
ing conditions would be ob-
vious if large lesions were
used. To dilute the study set,
150 non-cancer cases were
included.
The results of the study
are not yet available because
the study is still underway.
The results of the study may
have a profound impact on
the field of mammography
Periods of quiescence
may be punctuated by bouts
of recurrence, in some cases
throughout a lifetime. Even

















fusion or debilitating pain,
Fusion • 200714
requiring arthrodesis,1,2 the
surgical fusion of a joint
with the goal of pain relief.
Chronic pain, spontaneous
subtalar fusion or arthrodesis
can lead to an altered foot
movement, or gait, with






















therapy for a variety of joints
in children with JIA.4,5 Al-
though involvement of the
subtalar joint in the foot is
common in JIA, intra-articu-
lar treatment of this joint is
rarely attempted due to its
anatomic complexity and
resulting technical difficulty
in accessing the joint with-
out image guidance (Figure
1).
The purpose of this study
was to use fluoroscopically
guided intra-articular
subtalar steroid injection in
JIA patients with acute
symptoms to more accu-
rately access the joint and
relieve pain and increase
foot movement.
Fluoroscopically guided
subtalar joint injections were
performed in 38 children
(mean age 6.7 years). Medi-
cal records were reviewed
retrospectively and clinical
improvement was evaluated
by the degree of eversion
and inversion foot move-
ments.
Image-guided subtalar
joint injections were safely
and successfully achieved
with positive confirmation of
intra-articular steroid deliv-
ery in 100 percent of the JIA
patients. Improved range of
motion was seen in 34 of 38
subjects (89 percent) and 44
percent of the subjects re-
turned to a normal range of
motion. Regardless of the
elapsed time between injec-
tion and examination, clini-
cal improvement was defined
as increased foot eversion
and inversion at the follow-
up visit. Resolution was de-
fined clinically as normal
foot eversion and inversion
without clinical subtalar
symptoms. The mean dura-
tion of improvement was
found to be 1.1±0.9 years.
Notably, patients treated
within one year of onset of
Figure 1. Diagram of foot showing the
complexity of the location of the
subtalar (Talocalcaneal) joint. Intra-
articular treatment of this joint is
rarely attempted due to the technical
difficulty in accessing the joint
(Courtesy of Drake RL, Vogl, W,
Mitchell A. Moore K, Dalley A. Gray’s
Anatomy for Students. Philadelphia:
Elsevier; 2005).
subtalar symptoms were
more likely to improve than
patients treated more than
one year after subtalar symp-
toms were first diagnosed
(p=0.04).
This pilot work supports
an image-guided approach to
early treatment of joints af-
fected by inflammatory ar-
thritis, such as the subtalar
joint that is difficult to ac-
cess by palpation alone.
Once subtalar involvement is
identified, prompt referral
for treatment improves the
probability of clinical suc-
cess. Image-guided fluoros-
copy provides an accurate
way to treat the disease lo-
cally in its earliest stage.
Early treatment may help
avoid or delay development
of chronic and irreversible
joint changes and the associ-
ated pain and loss of func-
tion.
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2005;21(3):263-270.
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pathic arthritis. JAMA. 2005;
294:1671-1684.
4. Remedios D, Martin K,
Kaplan G, Mitchell R, Woo P,
Rooney M. Juvenile chronic
arthritis: diagnosis and man-
agement of tibio-talar and sub-
talar disease. Br J Rheumatol.
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5. Tynjala P, Honkanen V,
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Clin Exp Rheumatol. 2004;
22(5):643-648.
* This research was presented at the
2006 Society of Interventional Radiology
annual conference and is accepted for
publication in Pediatric Radiology.
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The purpose of this project
was to contribute to a na-
tionwide study aimed at de-
veloping new research and
treatment methods to help
individuals afflicted with
Paget’s sarcoma.
  Paget’s sarcoma is a rare
form of bone cancer that
develops in individuals who
are in the advanced stages of
Paget’s disease—a disease
characterized by abnormal
and excessive remodeling of
bone. In response to the
excessive osteoclastic bone
resorption, osteoblasts arrive
and fill in the areas of re-
sorption with new bone.
Due to the rapid activity
of osteoclasts, the osteoblasts
overreact and make excess
bone that is abnormally large
and chaotic. The resulting
bone is less dense and prone
to deformities and patho-
logic fractures. The disease
can affect one bone (monos-
totic) or multiple bones
(polyostotic). In the early
stages of the disease, the
affected bone becomes ten-
der and appears enlarged
upon x-ray (see Figure 1).
A small percentage of
patients with Paget’s disease
develop Paget’s sarcoma.
This usually occurs in indi-
viduals who have been af-
fected by polyostotic Paget’s
disease for many years. Pa-
tients with Paget’s sarcoma
present with severe, unremit-
ting pain, a palpable mass
around the involved bone
and often with a pathologic
fracture. Paget’s sarcoma is a
malignant bone tumor that
carries an extremely poor
prognosis.1
Paget’s Sarcoma: A Retrospective Review
Arun Rajaram, MSII
Advisor: Mark T. Scarborough, MD
University of Florida
Gainesville, FL
One of the primary rea-
sons for the high mortality
rate is that Paget’s sarcoma
mainly affects individuals
over 65 years old. In addi-
tion to the poor health of the
affected age group, the tu-
mors are extremely aggres-
sive and prone to pulmonary
metastases due to the in-
creased vascularity of the
affected bones.
This retrospective study
femur (four patients), radius
(one patient) and thoracic
vertebral body (one patient).
Due to the rapid progres-
sion of the tumors, radical
surgery needed to be per-
formed on most of the pa-
tients. Eleven amputations
and two wide surgical exci-
sions were conducted, and
three patients received radia-
tion therapy alone. Unfortu-
nately, most patients died
from lung metastases and
only two patients survived
the disease. The average
time from diagnosis to death
was 1.75 years (range: three
months to seven years).
Despite significant ad-
vances in the treatment and
survival of most bone sarco-
mas, Paget’s sarcoma re-
mains an extremely fatal
disease. The survival rate for
this cancer is less than 15
percent, despite the use of
aggressive surgery, radiation
and chemotherapy. Hope-
fully future research and new
treatment methods can be
developed to improve the
outcomes for patients with
this destructive malignancy.
REFERENCE:
1. Enneking W. Paget’s Disease.
Clinical Musculoskeletal Pathol-
ogy. Gainesville: University of
Florida Press; 1998:10:13-19.
consisted of 16 patients af-
flicted with Paget’s sarcoma.
The average age of cancer
onset was 67.5 (range: 52–
91) years old. Surprisingly,
there were three patients
diagnosed with Paget’s sar-
coma in their early 50s. In
the sample population, 75
percent of the patients were
male. The malignant tumor
affected only one bone in
nearly all of the patients.
However, in two individuals,
two different bones pos-
sessed the sarcomatous tu-
mor. One of these patients
possessed the cancer in the
femur and pelvis, while the
other patient was affected in
the humerus and pelvis.
Overall, the most frequently
affected bone, in seven pa-
tients, was the humerus.
Other afflicted sites included
the pelvis (four patients),
Figure 1. Paget’s sarcoma of the
humerus and radius1
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Medicine is stepping closer
to understanding how the
brain is used for language
and how ordinary language
organization may be re-
worked in patients with epi-
lepsy. A very effective,
noninvasive tool used to
study the brain is a func-
tional magnetic resonance
imaging (fMRI) scanner.
fMRI uses a conventional
magnetic scanner in a fash-
ion that allows rapid images
to be taken of brain activity.
Each region of a subject’s
brain used to perform a task
has a blood flow response
identifiable by the scanner.
This study examined scanner
responses in a large sample
of epilepsy patients and nor-
mal, healthy volunteers (con-
trols) under the clinical guid-
ance of pediatric neurologist
William Gaillard, MD, of
the Children’s National
Medical Center and the Na-
tional Institutes of Health.
Each participant in the
study was presented with a
language-related task while in
a 3 Tesla MRI scanner. Each
participant was given a series
fMRI Used to Define Language Organization in Epilepsy
Jay Zeck, MSII
Advisor: William Gaillard, MD
National Institutes of Health
Bethesda, MD
of simple sentences that were
true or not (e.g., “something
you sit on is a chair” or
“something you sit on is
spaghetti”). If the sentence
was true, the participant
pushed a button. Tracking
the performance helped en-
sure that the subject was
concentrating on the given
task while in the scanner.
Language centers tradi-
tionally reside in the left
hemisphere of the brain;
however, different patterns
persist more commonly in
epilepsy patient populations.1


















patients and the controls on
brain activation maps (see
Figure 1 for examples). The
geometric distances between
the points of activation in
the control versus patient
groups were then calculated.




epileptic interruption of lan-
guage networks. The epilepsy
patients with left hemisphere
language dominance used a
wider region of their domi-
nant temporal lobe to ac-
complish the same task as
the controls. In addition, the
region was significantly more
posterior and superior than
that of the controls. These
findings may indicate the
occurrence of dominant
hemisphere reorganization in
the wake of dominant hemi-
sphere epilepsy. Further-
more, this study notes that
pathology can also shift lan-
guage activation to the right
hemisphere, as shown by the
epilepsy patients. Language
centers of activation in these
individuals were found to
tightly cluster around a point
in the right hemisphere tem-
poral lobe that is otherwise
active on the left side in con-
trols.
These findings provide a
clearer picture of the distur-
bances that epilepsy can
cause. By showing differ-
ences in reorganization, re-
searchers can better define
how the brain can cope with
epilepsy. Still, the exact
mechanism of how epilepsy
interrupts language remains
unknown. However, know-
ing precisely what brain re-
gions epilepsy disturbs may
ultimately lead to under-
standing how it affects the
brain, which could impact
future treatments.
REFERENCE:
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Together with neurologist
William Gaillard, MD, and
his colleagues at Children’s
National Medical Center in
Washington, DC, studies




tion in children using func-
tional magnetic resonance
imaging (fMRI) and neurop-
sychological tests.
This research was part of
a larger project undertaken
to determine differences in
the location of language
function in the brains of
children with epilepsy. This
information would facilitate
the surgical removal of brain
tissue in children whose
epileptic seizures seriously




isolated primarily to the
temporal lobes of the left
hemisphere; however, pa-
tients with injury or im-
paired normal function of
brain tissue, as seen in
stroke or epilepsy, are likely
to have language functions
shifted to other areas of the
brain.1 Understanding this
shift is invaluable in plan-
ning neurosurgical interven-
tion and expanding our
knowledge of brain organiza-
tion and plasticity.
Epilepsy is a condition in
which normal signaling be-
tween neurons is disrupted,
resulting in paroxysmal peri-
ods of altered consciousness
Hippocampal Activation May Not Predict Memory for
Auditory Events
Shannon Gladman, MSII
Advisor: William Gaillard, MD
Children’s National Medical Center
Washington, DC
and stereotyped motor activ-
ity. Prior to resecting a por-
tion of brain tissue, a sur-
geon must ensure that areas
crucial to the patient’s nor-
mal function, such as lan-
guage, are not removed.
Neuropsychological tests
were administered on 42
children—21 epilepsy pa-
tients and 21 normal partici-
pants. Tests included the
Wide Range Assessment of
Memory and Learning
(WRAML) to evaluate each
child’s capacity for learning
and memory,2 and tests for
each child’s verbal intelli-
gence. The children then
listened to a two-and-a-half
minute story while undergo-
ing fMRI. Once removed
from the scanner, each child
was asked a series of ques-
tions about the story to as-
sess his or her memory per-
formance.
Using a magnetic field to
detect changes in blood flow
corresponding to changes in
neural activity, fMRI records
brain activation when a per-
son performs a particular
task—in this case, listening
to a story. After determining
which side of the brain had
the greatest language activa-
tion, a computer masking
program was used to isolate
hippocampal activation. The
hippocampi, located in the
medial temporal lobes of the
brain, are involved in learn-
ing and memory.
This study postulated that
the degree of left hippocam-
pal activation during a verbal
task would correlate with the
side of language dominance.
A relationship between hip-
pocampal activation and
language dominance was not
found, suggesting that injury
to the left hippocampus may
not mediate language reorga-
nization in the temporal neo-
cortex, which was recently
proposed as a mechanism of
language reorganization. A
more precise understanding
of learning and memory and
their relation to language
function during development
provides the basis for more
successful outcomes with
neurosurgical intervention in
cases of epilepsy and other
disorders.
REFERENCES:
1. Gaillard W. Functional MR





2. Adams W, Sheslow D.
WRAML: The Wide Range








tion in the tempo-
ral neocortex.
Fusion • 200718
Women who develop pri-
mary epithelial, fallopian
tube or peritoneal carcinoma
will most likely present with
advanced-stage disease.1 Op-
timal cytoreduction for ad-
vanced disease varies in lit-
erature from 15 to 85 per-




rates greater than 50 per-
cent.2,3
The optimal primary
cytoreduction rate at Memo-
rial Sloan-Kettering Cancer
Center (MSKCC) has been
less than 50 percent.  In
these cases, upper abdominal
resections were not per-
formed and thus residual
disease often involved the
diaphragm, liver and/or
spleen.4,5
In the beginning of 2001,
MSKCC modified its surgi-
cal approach to patients with
advanced ovarian, fallopian
tube or primary peritoneal
carcinoma by integrating
extensive upper abdominal




resection, resection of tumor
from the porta hepatis and
cholecystectomy. These
modified surgical procedures
were used at the discretion
of the primary surgeon to
obtain optimal residual dis-
ease status.6 This study com-
Comparison Study of Patients with Stages IIIC and IV
Epithelial Ovarian, Fallopian Tube and
Primary Peritoneal Cancers
Steven V. Kardos, MSI, Research Track
Advisor: Dennis Chi, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
pared surgical events and
results in patients who un-
derwent surgery between
January 1996 and December
1999 or between January
2001 and December 2004.
The latter group included
more extensive upper ab-
dominal resections.
of extensive upper abdomi-
nal surgical procedures and
the surgical prototype of the
service had not yet changed.6
Furthermore, patients
were excluded from the
study if they had completed
neo-adjuvant chemotherapy
or primary cytoreductive
surgery at another institu-
tion, or if they had low ma-
lignant carcinomas, such as
mucinous or carcinosarcoma
histologic types. In addition,
stage IIIC patients who did
not present with bulky dis-
ease greater than two centi-
meters, but rather presented
with positive lymph nodes,
were further screened out.
The following information
was extracted from the pa-
tients’ medical records: age
at diagnosis, date of primary
surgery, primary site of dis-
ease, tumor grade, histology,
pre-operative serum CA-125
level, platelet size, location of
largest tumor mass, amount
of ascites, surgical proce-
dures performed, size of
largest residual, site(s) of
residual tumor, estimated
blood loss, number of units
of blood transfused intraop-
eratively, intra-operative
complications, operative
time, length of hospitaliza-
tion, primary chemotherapy,
result of chemotherapy, date
of second look, outcome of
second look, last follow-up
and current state.
Although the data has
(Adapted from Drake RL, Vogl, W,
Mitchell A. Moore K, Dalley A. Gray’s
Anatomy for Students. Philadelphia:
Elsevier; 2005).
The MSKCC Gynecologic
Service Database was used to
compile information on all
patients with stages IIIC and
IV epithelial ovarian, fallo-
pian tube and primary peri-
toneal carcinomas.  These
patients had undergone pri-
mary cytoreductive surgery
at MSKCC between January
1996 and December 1999 or
between January 2001 and
December 2004.  Patients
who had undergone surgical
procedures from January
2000 to December 2000
were excluded from the study
because those surgeries did
not routinely include the use
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not yet been analyzed, the
hypothesis is that patients
who underwent surgery at
MSKCC between January
2001 and December 2004
show improved rates of opti-
mal primary cytoreduction
and survival over patients
who had surgery between
January 1996 and January
1999 when extensive upper
abdominal resections were
not performed.
The rising popularity of cu-
taneous laser surgery as an
accepted therapy for various
skin pathologies, coupled
with the diverse face of the
patient population, has led to
increasing demands for re-
searchers to investigate laser




shifting demographics in the
past decade, with 85 million
colored individuals in the
U.S. in 2000.1
However, most of the
current literature is devoted
to examining laser proce-
dures performed on indi-
viduals with fair skin tones
(skin phototypes I-II), and
protocols have largely been
defined on the basis of these
limited patient studies. This
research focuses on examin-
ing recent clinical research
of laser surgery on dark skin
tones to modify the stan-
dards for laser treatment of
vascular-specific, pigment-
specific, and ablative and
non-ablative skin resurfac-
ing.
Safe and Effective Laser Surgery on Dark Skin
Nirali Bhatt, MSII





be carefully considered when
performing laser surgery on
patients with darker skin.2,3
Although difficult, effec-
tive laser therapy in patients
with darker skin can be
achieved since the absorp-
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5. Redman J, Petroni G, Saigo P,
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factors in advanced ovarian
carcinoma. J Clin Oncol.
1986;4(4):515-523.
6. Chi D, Franklin C, Levine D,
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cytoreduction rates for stages
IIIC and IV epithelial ovarian,
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peritoneal cancer: a change in
surgical approach. Gynecol
Oncol. 2004;94(3):650-654.
 Due to its unusually wide
absorption spectrum ranging
from 250-1200 nanometer
(nm), melanin can be specifi-
cally targeted by all visible-
light and near-infrared (NIR)
dermatologic lasers currently
in use. In the darkly pig-
mented patient, nonspecific
energy absorption by rela-
tively large quantities of
melanin in the basal layer of
the epidermis can increase
unintended thermal injury
and lead to a higher risk of




tion and scarring. Treatment




lengths that are less effi-
ciently absorbed by endog-
enous melanin can often
provide a greater margin of
safety while still achieving
satisfactory results.9 Conser-
vative power settings should











to use in patients
with pale skin.
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minimize the extent of collat-
eral tissue damage. Clearly, a
prudent approach to treat-
ment is far preferable to





















ing from 532-600 nm. Since
577 nm represents a major
absorption peak of oxyhemo-
globin, the 585 nm
flashlamp-pumped pulsed
dye laser (PDL) has proven




red or NIR light to selec-
tively target intracellular mel-
anosomes, tattoo pigment or
to eradicate unwanted hair
by damaging follicular struc-
tures where melanin is
heavily concentrated. Q-
switched systems generating
nanosecond (ns) pulses that
are substantially shorter than
the 10-100 ns thermal relax-
ation time of melanosomes
represent the safest means
for treating pigmented le-
sions in dark skin.10
Q-switched systems cur-











nm ruby, 755 nm alexandrite
and 1064 nm Nd:YAG la-
Dermatologic lasers have
been used for more than
four decades to treat a vari-
ety of cutaneous conditions,
but, until recently, have been
wine stains in brown skin after
578 nm copper vapor laser
treatment. Lasers Surg Med.
1996;18(4):358-366.
6. Ho C, Nguyen Q, Lowe N,
Griffin M, Lask G. Laser
resurfacing in pigmented skin.
Dermatol Surg. 1995;21(12):
1035-1037.
7. Kim J, Lee J. Skin resurfacing
with laser in Asians. Aesthetic
Plast Surg. 1997;21(2):115-
117.
8. Ruiz-Esparza J, Gomex J, de la
Tarre O, Franco B, Vazquez
E. Ultrapulse laser skin resur-
facing in Hispanic patients: a
prospective study of 36 indi-
viduals. Dermatol Surg. 1998;
24(1):59-62.
9. Tanzi E, Lupton J, Alster T.
Lasers in dermatology: Four
decades of progress. J Am Acad
Dermatol. 2003;49(1):1-31.
10. Tse Y, Levine V, McClain S,
Ashinoff R. The removal of
(Courtesy of Gray, H. Anatony of the Human Body. Philadelphia: Lea & Febiger; 1973).
sers. The far-infrared wave-
lengths generated by the alex-
andrite and Nd:YAG laser
systems are less efficiently
absorbed by epidermal mela-
nin, which limits the extent
of unwanted thermal injury
to nontargeted tissues of the
epidermis and upper papil-
lary dermis, allowing for
deeper dermal penetration.
Cutaneous laser resurfac-
ing can provide an effective
means for improving the
appearance of diffuse dys-
chromia, photoinduced
rhytides and atrophic scar-
ring in patients with darker
skin phototypes. Several
reports document the long-
term safety of the high-en-






garnet (Er:YAG) lasers for
the treatment of more darkly
pigmented patients.11,12
limited to use in patients
with pale skin. This research
showed that recent develop-
ments in laser technology
have generated safe and ef-
fective means to treat pa-
tients with heavily pigmented
skin.
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Shikokho, Kenya
International Health Experience Shapes Future Path
Ikolomani Division, the
poorest division in the
Kakamega District in the
Western Province of Kenya.
Kakamega is the third poor-
est district of more than 70
in the country and is inhab-
ited mainly by subsistence
farmers of the Luhya tribe.
The estimated HIV rate for
the Western Province is
more than 25 percent.1
The developmental health
issues the Shikokho commu-
nity faces center on access.
Shikokho is 10 kilometers
(6.2 miles) away from the
nearest facility that can per-
form emergency services,
such as surgeries, or provide
free HIV testing and anti-
retroviral treatment. Add to
this that roads can only be
traversed by foot and be-
come virtually impassable
after a heavy rain. The dis-
tance and conditions prevent
a large sector of the popula-
tion from receiving critical
services.
One morning I visited St.
Elizabeth’s Hospital of
Mukumu, the nearest facility
with emergency services and
a government-approved HIV
testing and treatment facility.
I went to inquire about the
possibility of partnering with
the hospital for referrals of
emergency patients, includ-
ing the use of the ambulance
to Shikokho. Perhaps be-
cause I was a mzungu
(Swahili for white person),
the administrators agreed
and immediately gave me
four phone numbers for the
nurses at Shikokho to call to
transport a patient, including
mobile phone numbers for
the hospital administrator,
head doctor and matron
(nurse in charge). With this
assistance from St.
Elizabeth’s Hospital, an
emergency or serious health
problem would not result in
a death sentence for some-
one living in Shikokho.
During the third week of
My first patient in Kenya
died. On the first morning
of my eight-week internship
at the Shikokho Medical
Clinic, I was wide eyed and
ready to learn, but I could
hear a boy’s labored breath-
ing before I even entered the
clinic gate.
To treat what appeared to
be an asthma attack, the
nurses and I pumped as
many bronchodilators and as
much epinephrine as we
could into his small body.
Each injection did not sig-
nificantly help his breathing
as we had hoped and I felt
unsure of what to do next.
Without access to an emer-
gency phone number, ambu-
lance or viable transportation
out of the village to a bigger
or better equipped health
facility, the boy would die.
The nurses knew that. Since
there was no access to an-
other facility, the boy eventu-
ally stopped breathing.
It was difficult not to
think about the possibilities
that might have existed for
the boy in the U.S. with
access to proper emergency
care. But this was Shikokho,
Kenya, a small village of
about 1,500 where medical
and social problems are
vastly different from those in
America, and, at times,
seem grossly magnified.
Shikokho is part of
travel abroad. . .
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Although Costa Rica’s capital
and largest city serves as the
arrival and departure point
for many tourists, San José
is often overlooked by the
many sightseers who are
eager for more “exotic” at-
tractions.
Containing approximately
half of the entire country’s
population, the greater met-
ropolitan area of San José
consists of not only native
Costa Ricans but also a large
percentage (estimated at 40
percent) of Nicaraguan refu-
gees.1,2 They mostly live in
segregated areas around the
city where they struggle
against discrimination for a
better life. As a result of
their illegal status, many
Nicaraguans are denied
medical care.3 This article
discusses my personal expe-
riences working with Nicara-
guans in Costa Rica through
the Foundation for Interna-
tional Medical Relief of
Children (FIMRC), an orga-
my internship, a collabora-
tive effort by the Kenyan
Ministry of Health, the
World Health Organization
(WHO) and the United Na-
tions International Children’s
Education Fund (UNICEF)
allowed for a five-day distri-
bution of measles vaccina-
tions, Vitamin A and mos-
quito nets at all health facili-
ties in Kenya, including the
Shikokho Medical Clinic.
Previously, it had been an
enormous struggle to reach
young women isolated at
their shambas (farms).
This campaign gave the
clinic staff, including myself,
a unique opportunity to give
talks about malaria and the
proper use of mosquito nets
to more than 500 young
mothers in the community.
In the Western Province,
HIV prevalence is 4.8 per-
cent, but 5.8 percent among
women and 8.9 percent
among pregnant women.1
Agnes, a respected HIV-
positive midwife, gave sev-
eral health talks to the
women on the importance of
knowing one’s HIV status
and getting anti-retroviral
treatment if HIV positive.
The women responded en-
thusiastically and showed
appreciation to the clinic
staff for teaching them how
to prevent disease in them-
selves and their families.
During the last week of
my internship, the first HIV
voluntary counseling and
testing (VCT) day took place
at the Shikokho Medical
Clinic. After weeks of brain-
storming how to legally per-
form HIV testing at the
clinic, an arrangement was
made with St. Elizabeth’s
Hospital to perform a
monthly outreach at the
clinic. Using bars of soap as
incentive, the first VCT
event enabled 53 villagers,
including 12 pregnant
women, to be tested, coun-
seled and referred for treat-
ment when necessary.
After being introduced to
some of the critical health
problems facing the
Shikokho community during
my first week, I could not
have imagined some of the
creative solutions that
evolved in the following eight
weeks. I was told by many
people to move slowly and
cautiously and not expect to
see any results in this short
amount of time. This was
termed “realism.” But I
found it difficult to proceed
pole, pole (slowly by slowly)
when the urgency of these
life-and-death situations took
hold of me. Though the
health problems facing
Shikokho are by no means
solved, I was able to be a
part of many beginning
stages of solutions.
 Having this unique and
amazing experience as a
medical student opened my
eyes to international health
issues and how I can play a
role. I have felt the drive to
work in the realm of interna-
tional public health for many
years. This internship af-
firmed and solidified my
desire. I discovered strengths
and abilities I did not know
I possessed. I found that I
was driven by the needs of
the community and would
do almost anything in my
power to address these
needs. Instead of becoming
disillusioned by the many
obstacles, I became empow-
ered to do whatever I could
to help. I feel that my sum-
mer experience is best epito-
mized by former President
Jimmy Carter’s words,
“Once we understand, we
can care; and once we care,
we can change.”
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nization started by Vikram
Bakhru, MD, a GW medical
school alumnus who gradu-
ated in 2001. He is now in
his Surgery residency in
Philadelphia, but still man-
ages FIMRC. This article
discusses how such a popula-
tion can help volunteers un-
derstand and appreciate the
power of caring and compas-
sion in medicine.
I met FIMRC’s Medical
Director, Cristian Elizondo,
MD, the day after I arrived
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A View of “Los
Pinos” (The Pines),
a community outside











was limited to practicing
good medicine with his
words and his hands. I did
not see any life-saving proce-
dures or any serious cases
the week I was there, but the
patients taught me valuable
lessons and were a great tes-
tament to the foundation of
compassion and caring in
medicine. The genuine grati-
tude expressed by these















children hanging on her, one
woman kept a very patient
smile on her face while I
tried my best to take her
children’s histories. She even
wanted to take the time to
ask me about my life and my
work in Costa Rica. Most
patients were just happy
someone wanted to help and
care for them.
I took a second trip to
Costa Rica for a week in July
2006 when the new clinic
opened. An average of 20
patients visit the clinic daily
and FIMRC has expanded
its services to include a child
psychologist and a support
group for mothers suffering
from psychological problems
and abuse that often accom-
pany poverty. Dr. Elizondo
and everyone else at FIMRC
have worked hard to give the
Nicaraguan population a
sense of belonging, worth
and the relief that comes
with knowing someone is
there to help in times of
need. What I found to be
most memorable was that,
without fancy diagnostic
equipment or technology, we
were able to help and bring
hope to a population that
goes largely ignored. With so
much emphasis in the U.S.
on state-of-the-art medicines
and technologies, it was ex-
tremely valuable to see how a
doctor’s listening ear and
compassion could do so
in Costa Rica in February
2006. I expected to meet a
serious middle-aged physi-
cian, but I instead came
across a man not much older
than myself, wearing jeans
and a trendy T-shirt and jok-
ing with a friend on his cell
phone. Seeing this man re-
lieved me and his easygoing,
casual attitude alleviated my
previously grim and serious
outlook toward this volun-
teer project. Dr. Elizondo’s
demeanor and casual way of
dressing would have prob-
ably made people in the U.S.
skeptical or less confident in
him as a physician. But in
Costa Rica, this was very
appropriate. Dr. Elizondo
understood that his patients
felt most comfortable with
him if they could look at
him as a friend.
A new clinic was being
built by FIMRC, but it was
still under construction.
Over the next several days, I
visited some of the “ghet-















Utilizing my basic abili-
ties in Spanish, I helped with
patient charts, medication
distribution and health edu-
cation lessons as Dr.
Elizondo examined patients.
Without sophisticated equip-
ment or tests, Dr. Elizondo
much. With this lesson in
mind, I hope to be able to
always focus on the relation-
ships I establish with my
patients. My experience with
FIMRC and the people in
the Nicaraguan ghettos was
eye-opening, humbling and a
great way to remind me of
my future goals as a medical
student and beyond.
REFERENCES:
1. U.S. Department of State
Bureau of Western Hemi-
sphere Affairs. Background




2. Jones C. South to the Land of
Opportunity: Analyzing Nica-
raguan Emigration to Costa
Rica.  http://www.gwu.edu/
~lasp/Events/CEJones.pdf.
Accessed August 15, 2006.
3. Wallick S. Foundation for the
International Medical Relief
of Children:  Project





Most mammals make vita-
min C in the liver with en-
zymes that convert glucose
into vitamin C. Humans,
however, lost the ability to
do this. Therefore, humans
must get their vitamin C
from an outside source,
namely from their diet.
Vitamin C is necessary
for several important func-
tions in the body and for its
role as an antioxidant.1 On
the membranes of red blood
cells, vitamin E has the abil-
ity to reduce peroxides and
be regenerated by vitamin C.
Vitamin C is also known as
a water soluble, chain break-
ing donor antioxidant. Vita-
min C has the ability to re-
duce oxidative stress by ei-
ther slowing or preventing
the oxidative progression
before it even starts. It does
this by directly interacting
with the chain-carrying radi-
cals. It donates either a hy-
drogen atom or an electron
to the oxidant and is there-
fore able to prevent the
spread of cycle chain reac-
tions. As a powerful antioxi-
dant, vitamin C has been
shown to prevent atheroscle-
rosis, cancer and various
cerebral diseases.
Vitamin C, also known as
ascorbate, enters cells
through the Sodium Depen-
dent Vitamin C Transporter
2 (SVCT2). The oxidized
form, known as dehy-
droascorbic acid (DHA) and
obtained from the loss of
two electrons, enters cells
through the GLUT trans-
porter. Once DHA gets in-
side cells, it is immediately
reduced to ascorbate via
glutathione (GSH) or
through thioredoxin reduc-
tase. Ascorbate’s high con-
centration in neurons in the
brain shows that the brain
relies on vitamin C for its
antioxidant properties. Thus,
it is important to study how
cells take up and recycle
vitamin C.
HT-22 cells, a neuronal
cell line derived from mouse
hippocampus, were chosen
for this study because they
contain many SVCT2 and
GLUT transporters. Results
from a Western Blot showed
that the SVCT2 transporter
was present at 75 kilodaltons
(kD). Results from high-
performance liquid chroma-
tography (HPLC) showed
that as increasing amounts of
ascorbate were added to the
cells, there was a progressive
uptake of ascorbate up to 16
millimolar (mM) intracellular
concentration. When adding
increasing amounts of DHA
to the cells, there was a lin-
ear uptake of DHA and re-
duction to ascorbate, which
only went up to 1 mM ascor-
bate.
These results illustrated
that, since DHA is using the
GLUT transporter, glucose
could be competing with
DHA for entry into the cell.
When glucose was removed
and DHA was added to the
cells, a rapid linear increase
in the intracellular levels of
ascorbate was observed back
up to 16 mM, showing that
glucose was competing with
DHA for entry into the cell.
When increasing concentra-
tions of glucose were added
to the cell media, there was a
progressive decrease in
DHA uptake, and therefore
a decrease in recycling DHA
to ascorbate.
Clearly, glucose acts as a
competitive inhibitor. DHA
was shown to be dependent
on GSH for reduction to
ascorbate because when
agents that inhibited GSH
synthetase were added, there
was a 70-99 percent decrease
in intracellular ascorbate,
depending on the agent used.
When people without
diabetes are exposed to oxi-
dant stress, such as coronary
The Uptake, Recycling and Function of Vitamin C in
HT-22 Cells and its Relevance to Diabetes
Poonam Sood, MSII, Research Track
Advisors: James May, MD, and
Liying Li, MD
Vanderbilt Medical Center Division of
Diabetes, Endocrinology and Metabolism
Nashville, TN
at the bench. . .
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artery disease, some ascor-
bate gets oxidized to DHA
and goes into the area of
ischemia. Once DHA gets
into the cells, it is recycled
to ascorbate, a form that can
act as an antioxidant. DHA
uses GLUT transporters for
entry into cells. However,
people with uncontrolled
diabetes lose the ability to
uptake DHA due to the
competing nature of glucose.
Therefore, less DHA is re-
cycled to ascorbate and less
ascorbate indicates a de-
creased ability to deal with
oxidant stress. A diabetes
Type 2 diabetes mellitus is
one of the most significant
health threats in the world.
The World Health Organiza-
tion estimates that approxi-
mately 170 million people
are afflicted with this dis-
ease. Since this number is
expected to double within
the next two decades,1 it is
important to gain a better
understanding of the disease
and find better ways to con-
trol this growing problem.
 The type 2 diabetes mel-
litus whole genome associa-
tion study gathers genetic
variation2 by genotyping
Single Nucleotide Polymor-
phisms (SNPs), which are
variations of a single nucle-
otide that occur in at least
one percent of the popula-
tion, from patients with
adult onset type 2 diabetes
mellitus. This private-public
partnership, a collaboration
Performance of Statistical Models
On a Whole Genome Type 2 Diabetes Scan
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Advisor: Mark Daly, PhD
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between the Broad Institute,
Novartis Institutes for Bio-
medical Research and Lund
University in Sweden, pro-
motes open sharing of infor-
mation and hopes to show
that the benefits of this
openness will outweigh the
benefits of secrecy. After the
quality of the data is assured,
the primary analysis results
will be posted online for
public access.
For this research, case
and control subjects from
Sweden and Finland were
matched using two methods:
traditional case control and
discordant sibship. For the
traditional case control, one
or two subjects with adult
onset type 2 diabetes melli-
tus were matched with one
or two controls on the basis
of sex, body mass index
(BMI), age and geographical
region. The ages of the con-
patient who develops is-
chemia will have a problem
getting DHA into the cells
and recycling it back to
ascorbate.2 This is especially
important when considering
that the blood-brain barrier
lacks SVCT2 transporters
but contains DHA transport-
ers. Further studies are be-
ing conducted to see how
HT-22 cells deal with oxi-
dant stress, such as
glutamate, and the effect the
stress has on direct reduc-
tion with GSH and ascorbate
uptake.
The purpose of this
project was to better under-
stand the role of vitamin C
in the HT-22 cell line. If one
understands how these cells
use vitamin C, how vitamin
C gets recycled and what
effect these cells have on
oxidative stress, one can
then make connections with
the importance of certain
levels of dietary intake that
are required for vitamin C
to be beneficial to patients.
Researchers can then relate
these findings to diseased
states so that patients can
better understand the impor-
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trols were within 20 years of
the matching cases. The
cases and controls were seen
at the same clinical site and
were from the same geo-
graphical location. Cases and
controls were determined by
the ADA3 definition for type
2 diabetes and normal glu-
cose tolerance (NGT). For
discordant sibship, each
sibship group consisted of
three or four subjects, in-
cluding one or two affected
siblings and one or two unaf-
fected siblings. This group
was chosen using the same
selection criteria as the tradi-
tional case control.
 The study’s 2,881 sub-






data in terms of SNPs, this
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analysis requires the dataset
to be organized by genes.
One representation was cre-
ated by matching a compiled
list of 32,634 relevant genes
to the SNPs within and
around the gene. This repre-
sentation of genes was tested
under the stress of multiple
statistical methods to deter-
mine the statistical method
that most accurately embod-
ied the data.4,5  PLINK, a
whole genome association
analysis software toolset, was
used to analyze this data.
Three gene-based associa-
tion statistics were com-
pared: 1) Max: a statistical
method using the top-per-
forming chi square values for
each gene. 2) Sum: a statisti-
cal method using the sum
and normalization of up to
five chi square values for
each gene. 3) Hotelling’s T-
square: a multilocus, geno-
type-based test. The relation-
ships between the 10 best
performing genes of each
statistical method were ex-
amined. A subset of nine
genes, mentioned in litera-
ture and thought to be re-
lated to diabetes, were cho-
sen as a dataset of more
manageable size.
The release of these re-
sults is pending the comple-
tion of the project and the
public release of the genetic
and clinical information. In
the future, additional statisti-
cal methods will be used to
consider alternative repre-
sentations of genes, includ-
ing a model capturing epista-
sis (the interaction between
multiple genes) and sets of
related genes (such as the
genes in a particular meta-
bolic pathway).6, 7 Multiple
gene representations and
statistical tests will hopefully
create a clearer picture of
the genomic influence on
type 2 diabetes and eventu-
ally lead to a better under-
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A stimulating two-hour lec-
ture on human brain devel-
opment during my first year
of medical school motivated
me to seek a summer re-
search position in brain plas-
ticity and function. A Gill
Fellowship allowed me to
conduct research in the labo-
ratory of my Neurobiology
professor, Kenna Peusner,
PhD.
My project targeted the
changes in vestibular neu-
rons of the brainstem during
recovery of function after a
peripheral vestibular injury.
The vestibular system is pri-
marily responsible for main-
taining balance. Balance is
maintained by signaling in
three neuron reflex pathways
composed of vestibular gan-
glion cells in the periphery,
vestibular nuclei neurons in
the brain, and motor neu-
rons. After losing the vesti-
bular periphery on one side,
people exhibit symptoms of
nausea, vomiting, dizziness,
nystagmus, and the inability
to walk or eat. Without in-
tervention, most of these
symptoms disappear natu-
rally over the period of a
week, a process known as
vestibular compensation.
The present understanding is
that vestibular compensation
is due to brain plasticity,
involving a temporary loss of
neuronal excitability in vesti-
bular nuclei neurons and
their recovery. The process
occurs not only in humans,
but also in other vertebrates,
including birds. I chose the
hatchling chicken as my ex-
perimental model because
the chicken is bipedal like
humans, has particularly
distinctive vestibular nuclei
and young chickens show a
higher degree of brain plas-
ticity than adult chickens.1
The working hypothesis
of Dr. Peusner’s laboratory is
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Figure 1. An
immunocytochemical image of
the principal cell body located
in the vestibular system’s
tangential nucleus. The
brighter regions surrounding
the soma indicate a greater




events involved in establish-
ing neuronal excitability are
re-expressed during recovery
of function after injury. Fur-
thermore, the laboratory is
focused on investigating spe-
cific potassium channels
during vestibular compensa-
tion. In particular, I studied
a potassium channel that can
be identified because of its
sensitivity to the snake
venom dendrotoxin (DTX).
Surgery to remove the
vestibular periphery was
performed on four- to five-
day-old hatchling chickens,
which were sacrificed three
days afterward. Five-day-old
hatchlings were selected for
study because the neurons
achieve their mature excit-
ability at this age.2 During
embryonic development,
these neurons exhibit high
levels of this potassium chan-
nel, which is lost after reach-
ing maturity in five-day-old
chickens.3 I performed im-
munocytochemistry on five-
day-old normal chickens and
those with surgically re-
moved vestibular periphery
to determine whether the
level of expression of the
protein Kv1.2, an essential




I studied the principal
cells of the chicken tangen-
tial vestibular nucleus be-
cause these vestibular
nucleus neurons participate
in the vestibular reflex path-
ways (Figure 1).1 My project
involved learning immunocy-
tochemistry, behavioral test-
ing of operated hatchlings,
and confocal imaging and
analysis of these neurons. In
performing my tasks, I was
fortunate to have the oppor-
tunity to work alongside Dr.
Peusner as well as two re-
search scientists, Anastas
Popratiloff, MD, PhD, and
Mei Shao, MD, PhD.
I began my summer fel-





myself, I learned how deli-
cate and demanding micro-
surgery on the inner ear can
be. However,
immunolabeling the sections
proved to be the biggest
challenge. It was critical to
determine the appropriate
timing to avoid over- or un-
der-labeling the tissue sec-
tions with a particular anti-
body. Two secondary anti-
bodies were used to visualize
the neuron cell bodies and
their synaptic terminals with
Kv1.2. I learned the impor-
tance of using fluorescent
dyes with excitation and
emission curves that do not
overlap to prevent false posi-
tive labeling.
I mounted the prepared
brain sections on glass slides
for confocal imaging. This
specialized microscope took
a fair amount of practice,
but after a few days I gained
proficiency. Using confocal
microscopy and lasers of
varying frequencies, I im-
aged at 60x magnification
the Kv1.2 protein expressed
in the principal cells and
their synaptic terminals.
I captured confocal image
stacks containing 50 images
for each of 76 principal cells
and thousands of synaptic
terminals. Using Adobe
Photoshop 7.0, I outlined
the immunolabeled compo-
nents and analyzed the im-
ages for pixel brightness to
quantify the amount of
Kv1.2 protein expressed in
the synaptic terminals and in
the cytoplasm of the princi-
pal cells. Mean distribution
curves and standard devia-
tion of the data are in
progress. I am continuing to
work in Dr. Peusner’s lab
during the school year to
finish the project.
The work I performed in
Dr. Peusner’s lab taught me
many lessons, both practical
and philosophical. I became
proficient at using the confo-
cal microscope and I now
have a strong understanding
of digital image analysis. As
Dr. Popratiloff explained to
me, “Image analysis is a
highly evolving and useful
system in this new age of
digital computing.” I ac-
quired specific knowledge
and skills in behavioral test-
ing of experimental animals,
microsurgery and image
analysis that have carried
over into my classroom stud-
ies.
The scientific implica-
tions of this work will pro-




As these mechanisms are
better understood, molecular
targets will be identified and
more effective therapies may
be devised to treat central
vestibular disorders in hu-
mans resulting from disease,
injury or aging. From this, a
more concrete understanding
of brain plasticity and func-
tion may be achieved. As a
Gill Fellow, I witnessed first-
hand how ideas and hypoth-
eses about complex systems
of body function may be
explored in the laboratory,
and how the findings may be
translated to a better under-
standing of human health.
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Chemokines are a family of
low-molecular-weight pro-
teins that appear to be in-
volved in the costimulation
of T-cells. For this reason, in
addition to their well-estab-
lished role in chemotaxis,
chemokines are being inves-
tigated for their use in can-
cer immunotherapies.
Cancer immunotherapies
aim to harness the potential
of the body’s immune system
to combat malignant tumors.
When positive therapeutic
responses are achieved, they
are generally attributed to
the induction of cell-medi-
ated immune responses.1
This has proven challenging,
however, tumor cells appear
inherently effective at evad-
ing immune surveillance.
The poor immunogenicity of
these transformed, altered
self cells can be largely attrib-
uted to the suppressive na-
ture of the local tumor mi-
croenvironment, owing, in




critical in the activation of
naïve T-cells. Once the T-cell
receptor (TCR)/CD3 com-
plex has engaged its cognate
peptide-MHC presented by
an antigen-presenting cell
(APC), naïve T-cells must
receive a second signal to
drive clonal expansion and
differentiation into armed
effector cells. In the absence
of positive costimulation, T-
cells that have encountered
antigen become anergic,
Chemokines: Potentially Efficacious Cancer Vaccine
Adjuvants
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rendering them nonrespon-
sive. Thus, a costimulatory
molecule must be capable of
sending and/or receiving
information that initiates an
intracellular signaling path-
way that intersects with anti-
gen-specific signals synergis-
tically to allow for lympho-
cyte activation.3
Most costimulatory mol-
ecules belong to the B7/
CD28 and TNF/TNFR
families, while others belong
to the CD2-subset and
integrin/cell-adhesion mol-
ecule group.3 Their use in
cancer vaccines, often in
combination with a known
tumor-associated antigen,
offers a potentially effica-






ment, based upon their spa-
tial and temporal signifi-
cance to the initiation and
maintenance of the immune
response, immunotherapists
can help shift the balance
from immunotolerance, tu-
mor growth and survival to
T-cell activation and tumor
regression.2
An exciting finding is that
chemokines are emerging as
costimulatory molecules.4 Of
particular interest is CCL21,
a chemokine that is constitu-
tively expressed by secondary
lymphoid tissue and attracts
CCR7-expressing cells,
which largely include mature
antigen-experienced den-
dritic cells (DCs) and naïve
T-cells. The effective com-
munication between these
two cell types is crucial to
initiate cell-mediated im-
mune responses. For these
reasons, CCL21 is being
investigated for its role in
the coordinated migration of
these cell types, as well as its
ability to costimulate the
proliferation and differentia-
tion of naïve T-cells into
armed effectors.
Murine CCL21 has al-
ready been shown to
costimulate naïve T-cell ex-
pansion and Th1 polarization
of non-regulatory CD4+ T-
cells, and to a lesser extent,
the increased proliferation of
CD8+ T-cells.5 However, it
cannot be assumed that hu-
man CCL21 is capable of
the same, as significant dis-
crepancies exist between the
innate and adaptive immune






nuclear cells (PBMCs) with
the structurally related, but
functionally dissimilar
chemokines CCL3, CCL4
and CCL5.7 These three
chemokines are members of
the inflammatory chemokine
subfamily, whereas CCL21





expression profiles may carry
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Cancer is a leading cause of
death in the United States
each year. With current stan-
dard therapy options, the
long-term survival rate over a
five-year period hovers
around 65 percent.1
With a growing under-
standing of the immune sys-
tem, researchers have deter-
mined that the immune sys-
tem fights off foreign patho-
gens and is utilized against
malignancy.2 These discover-
ies have opened the door for




uses the body’s own natural
immune defenses to fight
cancer. It has two main ben-
efits over current treatment
options. With the use of
antibodies, therapeutic treat-
ment can be directly targeted
to specific tumor sites. This
allows for more concentrated
drug delivery and effective
results. Targeted delivery also





was engineered to bind to
intracellular antigens in de-
generating cells. The anti-
Second Messenger Activity with
Immune Cell Activation
Jennifer Goldstein, MSII, Research Track
Advisor: Alan Epstein, MD, PhD
Children’s Hospital of Los Angeles,
Keck School of Medicine of the
University of Southern California
Los Angeles, CA
implications toward their
intrinsic ability to function
in costimulation.8
As our interests are in-
clined toward translational
research, it is of great im-
portance to provide support-
ive evidence that the obser-
vations made in murine
models may also hold true in
the clinical setting. We have
begun to conduct numerous
in vitro cell proliferation
assays to test the ability of
human CCL21 to
costimulate cell division in
PBMCs, as well as sorted
CD4+ and CD8+ T-cells, all
of which have been har-
vested from healthy human
donors. Positive findings
here will help provide a sup-
portive rationale for integrat-
ing human CCL21 into can-
cer vaccines as an adjuvant
to therapy. As the immune
system is elegantly regulated
by a cascade of complex
interactions that resemble a
rheostat, rather than an on-
off switch,9
immunotherapists must tip
the balance of positive and
negative costimulatory sig-
nals in a way that achieves
appropriate levels of T-cell
activation that can lead to
the eradication of tumors,




of the chemokine family, can
allow for the fine tuning of
various spatial and temporal
aspects of cell-mediated im-
mune responses, helping to
increase the safety and effi-
cacy of cancer vaccines.
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body binds to necrotic re-
gions of solid tumors all
over the body.3-5 Specifically,
the liver expression
chemokine (LEC)/chTNT-3
fusion protein, which binds
to the necrotic region and
chemoattracts T-cells, B-
cells, and NK-cells to the
tumor site, has proven to
greatly reduce tumor load
and metastatic spread of the
tumor.6  However, the intra-
cellular consequences of
LEC binding to and activat-
ing immune cells are un-
known.
In this study, second mes-
senger and receptor tyrosine
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Figure 2. Changes in PKG
expression in THP-1-0
monocytic leukemia cells after
5 minutes, 1 hour and 18
hours of LEC stimulation for
PKG. Results were normalized
to actin to control for protein
loading discrepancies. Ox40
serves as a second control
sample.




cells after 5 minutes,





to control for protein
loading
discrepancies. Ox40
serves as a second
control sample.
kinase pathway protein ex-
pression levels were analyzed
by Western blot in THP-1-0
cells, a monocytic leukemia
cell line. Protein levels were
measured before and after
LEC stimulation to deter-
mine the intracellular signal-
ing molecules responsible for
immune cell activation.
Protein kinase C (PKC)
delta is a specific protein
kinase in the Phospholipase
C pathway, a very common
signal transduction pathway.
In previous LEC studies,
blockers of this pathway
have led to decreased
chemotactic activity in re-
sponse to LEC by immune




delta protein levels in mono-
cytic leukemia cell lines ex-
posed to LEC. A significant
change in PKC delta protein
levels was not seen, but there
was a significant increase in
phospho PKC delta protein
concentration 18 hours after
LEC stimulation (Figure 1).
These results indicate that
PKC delta plays a role in the
LEC stimulation pathway.
The JAK-STAT signaling
pathway takes part in the
regulation of cellular re-
sponses to cytokines and
growth factors. The pathway
transduces the signal carried
by extracellular polypeptides
to the cell nucleus, where
activated STAT proteins
modify gene expression. The
pathway plays a central role
in principal cell fate deci-
sions, regulating the pro-
cesses of cell proliferation,
differentiation and
apoptosis. It is particularly
important in hematopoiesis.
Because of its involvement in
blood cell gene expression,
we chose to look into its
possible role in immune cell
activation. There were no
significant changes in
STAT3, a protein-coding
gene involved in the JAK-
STAT pathway. There were
also no significant changes in
the catalytic subunit of pro-
tein kinase A (PKAc) in-
volved in another G protein
coupled receptor pathway.
Protein kinase G (PKG)
is another protein kinase
downstream to a G protein
coupled receptor pathway.
One hour after LEC stimula-
tion, THP-1-0 cells showed a
significant decrease in PKG
protein levels compared to
unstimulated cells (Figure 2).
These results elucidate the
intracellular signaling path-
ways involved in LEC-medi-
ated cellular activation. In
the future, these findings can
be used to understand the
mechanism of LEC-induced
immune cell recruitment to
fight cancer.
Another research project
aims to selectively knock out
T-regulatory cells from the
rest of the T-cell population
since T-regulatory cells limit
the immune response against
malignancy.8,9 This Western
blot technique could
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The physiological stress re-
sponse in animals, including
humans, is an adaptive
mechanism to fight or flee
from a threat. Observing this
response to stress in the














leads to a host of physiologi-
cal and mental disorders and
reduces the ability of the
organism to cope with its
environment. One of the
major stress-activated neu-
rotransmitters is neuropep-
tide Y (NPY), which appears
to inhibit the stress response
and improve memory in the
brain.1 The three goals of
this project were to elucidate
the neural mechanisms that
enhance learning and
memory under stress, iden-
tify the physiological limits
at which these mechanisms
ological stress response can
be quantified by measuring
associated changes in activa-
tion of the following systems:
sympathetic nervous (cat-
echolamines), adrenal corti-
cal (corticosterone) and car-
diovascular (heart rate and
blood pressure). To deter-
mine if these changes are
related to activation of the
NPY system in the brain,
expression of the peptide
and its receptors (Y1-Y5)
were studied in different
parts of the brain, including
the cortex, amygdala, hip-
pocampus and hypothala-
mus. It was predicted that
NPY would play a significant
part in modulating stress in
neurons.
In order to understand
NPY’s role in modulating
stress, mice were condi-
tioned by pairing an uncon-
ditioned stimulus/stressor
(mild electric foot shock)
with a battery of complex
auditory stimuli (harmonic
Experimental Solid Tumors by
Combination LEC/chTNT-3
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fail and determine the role of
NPY and its receptors in
these processes.
Auditory fear condition-
ing provides a quantifiable
paradigm for dissecting out
the neural circuits and syn-
aptic mechanisms that regu-
late memory and learning
and can be modified by












Erythropoietin’s Dual Role May Be More Harmful Than
Helpful in Cancer Patients
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Erythropoietin (EPO) is a
hormone that regulates red
blood cell production and is
a powerful drug used to
manage anemic patients.
However, recent evidence
suggests that EPO’s use in
treating anemic cancer pa-
tients may be more harmful
than helpful.
EPO, also known by its
trade names Procrit and
Epogen, is manufactured by
pharmaceutical giants
Johnson & Johnson (J&J)
and Amgen. It is one of the
10 most prescribed drugs in
the United States, with
nearly six billion dollars of
combined sales in the past
year. Clinical oncologists had
high hopes of using EPO to
treat cancer patients suffer-
ing from anemia, a common
side effect resulting from the
toxicity of radiation and
chemotherapy on the vascu-
lar system.
stacks of frequency modu-
lated sweeps). This estab-
lished a learning curve for
categorical perception of the
conditioned stimulus. Next,
NPY or specific NPY recep-
tor agonists were pressure
injected into the lateral ven-
tricles prior to conditioning
to see direct behavioral
changes to a stressor with
increased NPY.
Although NPY’s role in
the physiological stress re-
sponse has not yet been es-
tablished, there is strong
evidence suggesting a direct
mechanism in regulating the
cardiovascular system.
Intracerebro-ventricular in-
jection of NPY has been
shown to lower an increase
in heart rate associated with
auditory fear conditioning.2
It was also predicted that
this effect would reduce the
neuro-endocrine stress re-
sponse, thereby extending
the ability of the animal to
recognize fine distinctions
between categories of audi-
tory stimuli. Further insight
into NPY’s role will be gath-
ered by monitoring levels of
stress by measuring plasma
corticosterone levels and
heart rate prior to testing
and before and after fear
conditioning and changes in
NPY receptors in the rel-
evant brain areas.
Ongoing research will test
for any augmentation in the
stimulus-evoked local field
potentials (LFPs) in response
to the conditioned stimuli
within the amygdala and
hippocampus to localize the
sites of conditioned learning.
Mapping experiments will
determine stability (memory)
of the representation of
novel frequency modulation
stimuli with repeated condi-
tioning. The effects of ionto-
phoretic administration of
NPY or receptor agonists at
the recording site on the
spontaneous and stimulus-
evoked responses will be
studied as well as LFP re-
sponses at sites where aug-
mentation is observed. These
results will delineate the neu-
ral substrates and synaptic
mechanisms involved in con-
ditioned learning and the
role of stress in either aug-
menting or reducing this
effect. This knowledge will
shed light on how to prevent
the detrimental effects of
stress by either pharmaco-
logical or behavioral inter-
ventions during a stressful
experience rather than treat-
ing the physiological damage
from stress afterward at a
much greater cost.
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Two clinical trials de-
signed by J&J and Hoffman-
La Roche aimed to test the
safety and efficacy of EPO in
cancer patients. These trials
were prematurely terminated
when researchers discovered
high mortality rates and poor
disease-free survival in the
patient treatment groups that
were receiving EPO.
Until now, few researchers
understood the mechanism
behind such findings. The
laboratory of Ajay Verma,
MD, PhD, at the Uniformed
Services University of the
Health Sciences, has focused


































role in cancer. Recent stud-
ies by Dr. Verma that will be
published in the Journal of
Neurosurgery1 provide insight
on the underlying mecha-
nisms behind these clinical
observations. By studying the
roles of EPO and its recep-
tor (EPOR) in brain cancer
progression and invasion,
this research may have deter-
mined how EPO mediates
these deleterious conse-
quences.
The hypothesis was built
on several lines of research
that demonstrated that EPO
was a pleiotropic hormone
with a broad spectrum of
functions outside of the
hematopoetic system. Sev-
eral groups have demon-
strated that the EPOR is
found on tissues in addition
to red blood cell precursors,
including the brain, uterus
and breast (Figure 1). Sur-
prisingly, it is highly ex-
pressed on the surface of
cancer cells derived from
these tissues.1-3
Using several cancer cell
lines derived from tissues
utilizing EPO signaling, this
research showed that the
EPOR was highly
autocrine/paracrine mecha-
nism for tumor proliferation
and metastasis to escape
several tumor stressors, such
as local tumor hypoxia, that
develops from an imbalance
of tumor vascular supply to
tumor volume ratio.
To empirically approach
this hypothesis, a dominant
negative EPOR that was
missing the cytoplasmic do-
main for cell signaling was
developed. Inhibition of
EPO signaling in cancer cells
reduced proliferation, inva-
sion and in vivo tumor
growth in mice. Tumor vol-
umes of brain cancer cells
with truncated-EPOR trans-
planted in nude mice were
almost three to four times
smaller than control cells
(Figure 2).
This work provides in-
sight into how EPO pro-
motes cancer malignancy.
Human cancers express EPO
and functional EPORs. High
expression of these proteins
in several human cancers
makes EPO signaling an
attractive therapeutic target
and underscores the impor-
tance of reevaluating the
indiscriminate use of EPO
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upregulated in these cells
compared to normal tissue.
In fact, administration of
pharmaceutical EPO pro-
moted cancer cell prolifera-
tion and invasion. It was
postulated that ectopic EPO
and EPOR expression in
tumors is used as an
Fusion • 200734
Duchenne muscular dystro-
phy (DMD) is a degenera-
tive muscle wasting disease
caused by mutations in the
dystrophin gene. DMD has
a high incidence in all world
populations, due to the high
rate of new mutations in the
dystrophin gene. DMD pa-
tients show myofiber mem-
brane instability from birth.
Muscle weakness usually
begins around age four fol-
lowed by a gradual replace-
ment of skeletal muscle with
fibrous and fatty tissue.1
Transforming growth
factor beta (TGF-ß) is a fam-
ily of proteins secreted by
many cell types. These pro-
teins regulate a variety of
cellular processes and have
been implicated in many
disease processes, including
DMD.2 For example, with
some vascular conditions,
such as pulmonary hyperten-
sion, TGF-ß1 has been
shown to stimulate excess
synthesis of extracellular
matrix proteins and inhibit
matrix degradation.3 Addi-
tionally, TGF-ß1 inhibits in
vitro myoblast proliferation
in some cultured muscle cell
lines and primary myogenic
cells.4 It also suppresses pro-
liferation and delays muscle
regeneration in vivo.4 It has
been demonstrated that
TGF-ß1 secretion by C2C12
myoblasts leads to down-
regulation of myogenic pro-
teins such as MyoD and
increased expression of fi-
brotic proteins.5
Insulin-like growth factor
binding protein 3 (IGFBP3)
has recently been shown to
interact with the TGF-ß
pathways. IGFBP3 has been
shown to suppress prolifera-
tion of various cell types by
blocking cell cycle and in-
ducing apoptosis.6,7 Besides
their IGF-dependent mecha-
nism of action, IGFBP3 may
affect cells by IGF-indepen-
dent mechanisms including
binding to cell surface recep-
tors, including the TGF-ß1
receptors.7-9 Recent studies
show that IGFBP3 is
upregulated in mid-to-late
stages of DMD. Currently,
research is being performed
to test the hypothesis that
TGF-ß1 pathways lead to
fibrosis and defects in
muscle regeneration, which,
in turn, leads to muscle wast-
ing in later stages of DMD.
Also, there is ongoing re-
search to identify down-
stream targets of TGF-ß1.
In this research, the ef-




study stemmed from the
hypothesis that the inhibi-
tion of myogenesis/regenera-
tion of dystrophin-deficient
muscle in later stages of
DMD is mediated, at least
in part, by IGFBP3.
This research used the
mouse myoblast cell line
C2C12. These cells have the
ability to become skeletal
muscle cells and are often
used in experiments looking
at myogenesis (skeletal
muscle development) and cell
differentiation. Bbecause
they are cells that are not
terminally differentiated, one
can see how external factors
affect the process of these
less mature cells becoming
more mature skeletal muscle
cells.
C2C12 cells were incu-
bated in differentiation me-
dium containing Dulbecco's
Modified Eagle's Medium
(DMEM), two percent fetal
bovine serum and penicillin/
streptomycin (1:100) to fa-
cilitate cell maturation with
and without TGF-ß1 for 72
hours. Cell differentiation
was inhibited in cells treated
with higher TGF-ß1 concen-
trations compared to cells
treated with lower TGF-ß1
concentrations or cells not
treated with TGF-ß1 at all. It
is likely that the exposure to
high concentrations of TGF-
ß1 led to the downregulation
of myogenic proteins, such
as MyoD, and the
upregulation of fibrosis-re-
lated proteins, such as
fibronectin. As a result, cul-
tures with a high concentra-
tion of TGF-ß1 showed
fewer myotubes (Figure 1).
In cultures with no TGF-
ß1 and low concentrations of
TGF-ß1, the transition from
expression of myogenic pro-
teins to fibrotic proteins
does not likely occur to the
extent as in cultures with
high concentrations of TGF-
ß1. Thus, in cultures where
the frequency of myoblasts
was high, expression of the
Effects of TGF-ß1 on Cell Differentiation and
IGFBP-3 Expression in C2C12 Myocytes
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Figure 1. C2C12 cells in culture after 72 hours without TGF-ß1 (above) and with a
high concentration of TGF-ß1 (below). Cells without TGF-ß1 show a high degree of
myotube formation, whereas formation seems to be inhibited with a high
concentration of TGF-ß1.
MyoD family of transcrip-
tion factors was likely high,
leading to myogenic differen-
tiation by expression of vari-
ous muscle specific genes.10
An increase in IGFBP3
expression due to TGF-ß1
was previously shown in
various cells.11-13 Levels of
IGFBP3 and TGF-ß1 have
been shown to be higher in
patients in later stages of
DMD, and it was hypoth-
esized that the muscle wast-
ing and increased fibrosis
seen in later stages of DMD
was the result of TGF-ß1
pathways upregulating
IGFBP3. Our results, how-
ever, do not show a correla-
tion between TGF-ß1 expo-
sure and IGFBP3 expression
in C2C12 myoblasts. These
studies may need to be re-
peated with greater sample
size to confirm the results.
While TGF-ß1 and
IGFBP3 expression may not
be correlated in mouse
C2C12 myoblasts, it is pos-
sible that this relationship
does exist in other species,
including humans. Other cell
lines, particularly primary
cells, should be tested.
Studying the effects of mo-
lecular pathways, such as the
TGF-ß1 pathway, is impor-
tant because it may eventu-
ally lead to a model for
DMD pathogenesis and un-
cover potential targets of





Rosenberg RN, Prusiner S,
DiMauro S, Barchi R, eds.
The Molecular and Genetic
Basis of Neurologic and Psychi-
binding protein-3 in T47D
breast cancer cells requires
TGF- and the type II TGF-
receptor. Journal of Biological
Chemistry. 2000;275(50):
39146-39151.
8. Gui Y, Murphy L. Interaction
of insulin-like growth factor
binding protein-3 with latent
TGF- binding protein-1.
Molecular & Cellular Biochem-
istry. 2003;250(1-2):189-195.
9. Kamanga-Sollo E, Pampusch
M, White M, Dayton W.
Role of insulin-like growth
factor binding protein
(IGFBP)-3 in TGF- - and
GDF-8 (myostatin)-induced
suppression of proliferation in
porcine embryonic myogenic
cell cultures. Journal of Cellu-
lar Physiology. 2003;197(2):
225-231.
10. Liu D, Black B, Derynck R.
TGF- inhibits muscle differen-
tiation through functional
repression of myogenic tran-
scription factors by Smad3.
Genes & Development. 2001;
15(22):2950-2966.
11. Kveiborg M, Flyvbjerg A,
Eriksen E, Kassem M. TGF-
ß1 stimulates the production
of insulin-like growth factor-I
and insulin-like growth factor-
binding protein-3 in human
bone marrow stromal osteo-
blast progenitors. Journal of
Endocrinology. 2001;169(3):
549-561.




binding protein (IGFBP)-3 in
human breast cancer cells.
Progress in Growth Factor Re-
search. 1995;6(2-4):503-512.
13. Yi Z, Hathaway M, Dayton
W, White M. Effects of
growth factors on insulin-like
growth factor binding protein
(IGFBP) secretion by primary
porcine satellite cell cultures.





5. Li Y, Foster W, Deasy B, et al.
TGF-ß1 induces the differen-
tiation of myogenic cells into
fibrotic cells in injured skeletal




6. Baxter R. Signaling pathways
involved in antiproliferative
effects of IGFBP-3: a review.
Molecular Pathology. 2001;
54(3):145-148.
7. Fanayan S, Firth S, Butt A,
Baxter R. Growth inhibition
by insulin-like growth factor-
atric Disease. 3rd ed. London:
Butterworth-Heinemann;
2003:467-478.
2. Ishitobi M, Haginoya K, Zhao
Y, et al. Elevated plasma levels




3. Bernasconi P, Di Blasi C,
Mora M, et al. TGF-ß1 and
fibrosis in congenital muscular
dystrophies. Neuromuscular
Disorders. 1999;9(1):28-33.
4. Zhu S, Goldschmidt-
Clermont P, Dong C. TGF-ß-
induced inhibition of
myogenesis is mediated
through Smad pathway and is
Fusion • 200736
The difference could be in
an atom or two. When read-
ing the structural maps of
proteins, a crystallographer
tries to accurately determine
the location of an amino
acid building block, side
chain or substrate molecule.
Within the limits of technol-
ogy, the crystallographer
must carefully identify mol-
ecules, attempt to discover
the order of nature and per-
haps learn why a potential
drug may be able to fight
cancer.
Glycosylation is the “orna-
menting” process of all cells.
Tumor cells that display spe-
cific sugar “ornaments” are
directly involved in the me-
tastasis of certain lung and
colon cancers. Preliminary






















X-ray Crystallographic Studies on the Binding
Mechanism of a Potential Antimetastatic Molecule
Najma Khorrami, MSI, Research Track






To see how the molecule
fits into the substrate bind-
ing “pocket” of 1,4-
galactosyltransferase, form-
ing the crystal structure of
the enzyme-substrate com-
plex was vital. High-quality
crystals were obtained with
the human mutant enzyme,
Met344His-Gal-T1,3 bound




purifying the enzyme to
about 99 percent homogene-
ity. Figure 1 shows crystals
of the mutant
galactosyltransferase in com-
plex with the disaccharide
obtained after 48 hours.
I began to learn the steps
involved in protein crystal-
lography as part of my sum-
mer internship in Dr.
Pradman Qasba’s lab at the
National Cancer Institute in
Frederick, MD, under Dr.
Boopathy Ramakrishnan’s
mentorship.
I learned how to crystal-
Figure 1. Crystals of
the mutant
galactosyltransferase









the order of nature
and perhaps learn
why a potential
drug may be able to
fight cancer.
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lize the enzyme, given a rela-
tively complex recipe from
Dr. Ramakrishnan. In one of
my first attempts to crystal-
lize the disaccharide sub-
strate with the enzyme, I
plated a set of 18 wells with
microliter-sized protein
droplets and waited for crys-
tals to appear.
After waiting 48 hours,
using the hanging drop vapor
diffusion method (in which
the basis for crystallization is
a concentration gradient
between the droplet and sol-
vent within the same well), I
noticed a large diamond-
shaped crystal in a droplet
under the microscope. While
some parts of the crystalliza-
tion process were tedious,
others made the wait and the
work seem near trivial.
Preliminary x-ray results
showed that the disaccharide
compound bound to the
substrate site with equal or
higher affinity than a natural
trisaccharide molecule ana-
lyzed previously.4 The results
support the hypothesis that
the disaccharide “decoy” is
able to bind tightly to the
molecule and divert
glycosylation of natural sub-
strates and ultimately inhibit
tumor cells from binding to
blood platelets, which en-
ables the cancer to metasta-
size.
The normal glycosylation
process is close to, but not
exactly, what happens when
the “decoy” is in place.
Here, a dangling naphthalene
molecule, which is bound to
the disaccharide, conforms
to the substrate binding site
similarly to the third sugar
molecule in the natural
trisaccharide. Eventually,
“cloaking” occurs with cells





obtained after 48 hours
(Courtesy of Najma
Khorrami)
missing the natural trisaccha-
ride, triggering hematog-
enous metastasis.
Jillian R. Brown, PhD, of
the University of California
will continue experimental
studies using the “decoy”
disaccharide compound. Her
clinical-focused research on
the molecule’s ability to tar-
get colon and lung cancer
cell metastasis, both in vitro
and in vivo, has lasted close
to five years. She under-
stands the important benefits
of a potential antimetastatic
drug if it entered the market.
“Nothing clinically useful
is available for the treatment
of metastasis,” says Dr.
Brown. “At the molecular
level, there are lots of hy-
potheses but little is known
(mechanistically).” The stud-
ies conducted in the labora-
tory of Jeffrey Esko, PhD at
the University of California,
have examined the
disaccharide’s ability to in-
hibit metastasis in rats by
limiting the ability of tumor
cells to proliferate in the
body by binding to blood
platelets via signature sugar
chains on cell membranes.
“The idea of compounds
acting as ‘primers’ by decoy-
ing the synthesis of endog-
enous glycoconjugates has
been ongoing in our lab for
many years. The first identi-
fication was in an experi-
ment with U937, a human
lymphoma cell line,” says
Dr. Brown. “Now, the disac-
charide is being developed
further and will enter pre-
clinical trials as an
antimetastatic agent.”
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Fusion is the annual publication of the GW chapter of The Beaumont Society
to showcase student achievements in the fields of biomedical research,
public health research, clinical research and international health related
travel experiences.
Submissions for next year’s issue of the journal will be accepted
beginning September 2007 from the Class of 2010 as well as the
incoming Class of 2011. More information about the submission process
will be provided during the summer of 2007. If students have any
questions or comments, contact the Beaumont Society at gwbeaumont@gmail.com.
Contributions to the publishing costs of this journal are appreciated. If you would like to make a
donation, please contact us at gwbeaumont@gmail.com. All proceeds will go toward the publishing
costs for next year’s journal for next year.
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The William H. Beaumont Society is an honorary research society of medical students that
was established in 1935 in honor of Dr. William Beaumont, a pioneer in physiology
research.  The organization seeks to foster a continuing interest in biomedical research and to
promote its value in the practice of medicine.  As a part of this mission, the Society integrates
current research topics with the curriculum, develops a research journal showcasing GW stu-
dent research, makes available information on research opportunities and seminars throughout
the area, including the William T. Gill Summer Fellowship for GW medical students, and high-
lights student and faculty research accomplishments at the annual GW Research Day.
about beaumont society . . .
Beaumont
Leaders
2006-2007 officers of the William
H. Beaumont Society at The George
Washington University include, top
row, from left: Andrew Lerner,
president; Vivek Patil, co-vice
president; Steven Kardos,
secretary; and Rahul Arya, research
journal chair; seated, from left:
Rasha Al-Bawardi, co-vice
president; Jennifer Goldstein,
research day coordinator; and Ajay
Wadgaonkar, MSI student
representative.
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